Low expression of aldehyde deyhdrogenase 1A1 (ALDH1A1) is a prognostic marker for poor survival in pancreatic cancer

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Kahlert, Christoph ^a   Bergmann, Frank ^b   Beck, Janine ^a   Welsch, Thilo ^a   Mogler, Carolin ^b   Herpel, Esther ^b   Dutta, Shamik ^a   Niemietz, Thomas ^a   Koch, Moritz ^a   Weitz, Jürgen ^a  

^a Visceral and Transplantation Surgery ^*  (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

ALDH1A1; Pancreatic cancer; Prognostic marker; Proliferation rate

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE 1A1; ANTINEOPLASTIC AGENT; KI 67 ANTIGEN; UNCLASSIFIED DRUG; ALDH1A1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM VESICLE; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE MARKER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PRIMARY TUMOR; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; WESTERN BLOTTING; ADJUVANT CHEMOTHERAPY; BIOSYNTHESIS; CELL DIVISION; COHORT ANALYSIS; ENZYME IMMUNOASSAY; ENZYME INDUCTION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PANCREAS CARCINOMA; PANCREAS RESECTION; PANCREAS TUMOR; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TUMOR CELL LINE;

AGED; ALDEHYDE DEHYDROGENASE; CARCINOMA, PANCREATIC DUCTAL; CELL DIVISION; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COMBINED MODALITY THERAPY; ENZYME INDUCTION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL;

EID: 79959540301     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-275     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008, 58(2):71-96. 10.3322/CA.2007.0010, 18287387.
2. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993, 165(1):68-72. discussion 72-63, 10.1016/S0002-9610(05)80406-4, 8380315.
3. Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006, 244(1):10-15. 10.1097/01.sla.0000217673.04165.ea, 1570590, 16794383.
4. Delcore R, Rodriguez FJ, Forster J, Hermreck AS, Thomas JH. Significance of lymph node metastases in patients with pancreatic cancer undergoing curative resection. Am J Surg 1996, 172(5):463-468. discussion 468-469, 10.1016/S0002-9610(96)00237-1, 8942545.
5. Hellan M, Sun CL, Artinyan A, Mojica-Manosa P, Bhatia S, Ellenhorn JD, Kim J. The impact of lymph node number on survival in patients with lymph node-negative pancreatic cancer. Pancreas 2008, 37(1):19-24. 10.1097/MPA.0b013e31816074c9, 18580439.
6. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM. Identification of pancreatic cancer stem cells. Cancer Res 2007, 67(3):1030-1037. 10.1158/0008-5472.CAN-06-2030, 17283135.
7. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1(3):313-323. 10.1016/j.stem.2007.06.002, 18371365.
8. Maeda S, Shinchi H, Kurahara H, Mataki Y, Maemura K, Sato M, Natsugoe S, Aikou T, Takao S. CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer 2008, 98(8):1389-1397. 10.1038/sj.bjc.6604307, 2361715, 18349830.
9. Gotoda T, Matsumura Y, Kondo H, Saitoh D, Shimada Y, Kosuge T, Kanai Y, Kakizoe T. Expression of CD44 variants and its association with survival in pancreatic cancer. Jpn J Cancer Res 1998, 89(10):1033-1040.
10. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1(5):555-567. 10.1016/j.stem.2007.08.014, 2423808, 18371393.
11. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, Fields JZ, Wicha MS, Boman BM. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009, 69(8):3382-3389. 10.1158/0008-5472.CAN-08-4418, 2789401, 19336570.
12. Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, Wang H, Liu Z, Su Y, Stass SA, et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 2009, 7(3):330-338. 10.1158/1541-7786.MCR-08-0393, 19276181.
13. Chen YC, Chen YW, Hsu HS, Tseng LM, Huang PI, Lu KH, Chen DT, Tai LK, Yung MC, Chang SC, et al. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun 2009, 385(3):307-313. 10.1016/j.bbrc.2009.05.048, 19450560.
14. Yoshida A, Rzhetsky A, Hsu LC, Chang C. Human aldehyde dehydrogenase gene family. Eur J Biochem 1998, 251(3):549-557. 10.1046/j.1432-1327.1998.2510549.x, 9490025.
15. Hilton J. Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Cancer Res 1984, 44(11):5156-5160.
16. Patel M, Lu L, Zander DS, Sreerama L, Coco D, Moreb JS. ALDH1A1 and ALDH3A1 expression in lung cancers: correlation with histologic type and potential precursors. Lung Cancer 2008, 59(3):340-349. 10.1016/j.lungcan.2007.08.033, 17920722.
17. Rasheed ZA, Yang J, Wang Q, Kowalski J, Freed I, Murter C, Hong SM, Koorstra JB, Rajeshkumar NV, He X, et al. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst 102(5):340-351.
18. Chang B, Liu G, Xue F, Rosen DG, Xiao L, Wang X, Liu J. ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod Pathol 2009, 22(6):817-823. 2692456, 19329942.
19. Lugli A, Iezzi G, Hostettler I, Muraro MG, Mele V, Tornillo L, Carafa V, Spagnoli G, Terracciano L, Zlobec I. Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44 s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer 103(3):382-390.
20. Morimoto K, Kim SJ, Tanei T, Shimazu K, Tanji Y, Taguchi T, Tamaki Y, Terada N, Noguchi S. Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci 2009, 100(6):1062-1068. 10.1111/j.1349-7006.2009.01151.x, 19385968.
21. Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, Tamaki Y, Noguchi S. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 2009, 15(12):4234-4241. 10.1158/1078-0432.CCR-08-1479, 19509181.
22. Kahlert C, Weber H, Mogler C, Bergmann F, Schirmacher P, Kenngott HG, Matterne U, Mollberg N, Rahbari NN, Hinz U, et al. Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse. Br J Cancer 2009, 101(3):457-464. 10.1038/sj.bjc.6605136, 2720248, 19603023.
23. Barbareschi M, Maisonneuve P, Aldovini D, Cangi MG, Pecciarini L, Angelo Mauri F, Veronese S, Caffo O, Lucenti A, Palma PD, et al. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 2003, 98(3):474-483. 10.1002/cncr.11515, 12879463.
24. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic acids research 2001, 29(9):e45. 10.1093/nar/29.9.e45, 55695, 11328886.
25. Walsh N, O'Donovan N, Kennedy S, Henry M, Meleady P, Clynes M, Dowling P. Identification of pancreatic cancer invasion-related proteins by proteomic analysis. Proteome Sci 2009, 7:3. 10.1186/1477-5956-7-3, 2646716, 19216797.
26. Makinen K, Hakala T, Lipponen P, Alhava E, Eskelinen M. Clinical contribution of bcl-2, p53 and Ki-67 proteins in pancreatic ductal adenocarcinoma. Anticancer Res 1998, 18(1B):615-618.
27. Stanton KJ, Sidner RA, Miller GA, Cummings OW, Schmidt CM, Howard TJ, Wiebke EA. Analysis of Ki-67 antigen expression, DNA proliferative fraction, and survival in resected cancer of the pancreas. Am J Surg 2003, 186(5):486-492. 10.1016/j.amjsurg.2003.07.002, 14599612.
28. Stocken DD, Buchler MW, Dervenis C, Bassi C, Jeekel H, Klinkenbijl JH, Bakkevold KE, Takada T, Amano H, Neoptolemos JP. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 2005, 92(8):1372-1381. 10.1038/sj.bjc.6602513, 2361989, 15812554.
29. Gong C, Yao H, Liu Q, Chen J, Shi J, Su F, Song E. Markers of tumor-initiating cells predict chemoresistance in breast cancer. PLoS One 5(12):e15630.
30. Monti P, Marchesi F, Reni M, Mercalli A, Sordi V, Zerbi A, Balzano G, Di Carlo V, Allavena P, Piemonti L. A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile. Virchows Arch 2004, 445(3):236-247. 10.1007/s00428-004-1053-x, 15258755.